QOP
PACB icon

Quinn Opportunity Partners’s Pacific Biosciences PACB Stock Holding History

Quinn Opportunity Partners’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-40,514
Closed -$124K – 198
2020
Q1 		$124K Buy
+40,514
New +$166K 0.02% 156

Other funds holding PACB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KLCMU
Kite Lake Capital Management (UK) London, United Kingdom $125M AUM 198.01% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Quinn Opportunity Partners's PACB Position: Q2 2020 in Review

Quinn Opportunity Partners sold out of Pacific Biosciences (PACB) in Q2 2020, closing a stake of 40,514 shares — an estimated $124K sold.

Quinn Opportunity Partners first reported a position in PACB in Q1 2020 and held it in 1 quarter. The position peaked at $124K in Q1 2020. 151 funds tracked by Wall St. Rank hold PACB as of Q2 2020.

  • Quinn Opportunity Partners reported no remaining Pacific Biosciences position as of Q2 2020 after selling out during the quarter.
  • Quinn Opportunity Partners sold 40,514 Pacific Biosciences shares in Q2 2020, an estimated $124K.
  • Quinn Opportunity Partners first reported a position in Pacific Biosciences in Q1 2020 and held it in 1 quarter.
  • Quinn Opportunity Partners's Pacific Biosciences position peaked at $124K in Q1 2020.
  • 151 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2020.

Based on Quinn Opportunity Partners's 13F filing for Q2 2020, filed 14 Aug 2020.